Last December, Xanodyne Pharmaceuticals agreed to stop selling Darvocet in the U.S. after the evidence of cardiac injuries from Darvocet reached critical mass. Darvocet lawsuits are now being filed in massive numbers. Yesterday, in San Francisco, Plaintiffs’ Darvocet lawyers argued that all of the federal Darvocet cases should be centralized in an MDL which is sort of, but not really, a class action lawsuit.
These are the main points made in Darvocet lawsuits:
- Xanodyne Pharmaceuticals concealed their knowledge of Darvocet’s risks from plaintiffs, the medical community, the FDA, and the American people.